Compass Therapeutics, Inc.
CMPX Healthcare Biotechnology
Compass Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $850,000.00. In the quarter to June 2026, EPS grew 7.14% and free cash flow fell 26.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow CMPX
Compass Therapeutics, Inc. (CMPX) Altman Z-score
Compass Therapeutics, Inc.'s Altman Z-score for fiscal 2024 is 3.98, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2024 | 3.98 | — |
How fiscal 2024’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.88 | — | 1.06 | |
| Retained earnings / total assets | (2.60) | — | −3.64 | |
| EBIT / total assets | (0.40) | — | −1.33 | |
| Market value of equity / total liabilities | 13.13 | — | 7.88 | |
| Sales / total assets | 0.01 | — | 0.01 | |
| Altman Z-score | Safe zone | 3.98 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 3.28 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| CMPX Compass Therapeutics, Inc. | 4.0× |
| ORMP Oramed Pharmaceuticals Inc. compare | 1.9× |
| WHWK Whitehawk Therapeutics, Inc. compare | 1.5× |
| MDWD MediWound Ltd. compare | −1.1× |
| DTIL Precision BioSciences, Inc. compare | −4.3× |
| ADAG Adagene Inc. Sponsored ADR compare | −4.6× |
| CHRS Coherus Oncology, Inc. compare | −8.8× |
| IPHA Innate Pharma S.A. Sponsored ADR compare | −11.2× |
| VRXA Veraxa Biotech AG compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets